D-0331-2026 Class II Ongoing

Recalled by F.H. INVESTMENTS, Inc. (Dba Asteria Health) — Birmingham, AL

FDA drug recall D-0331-2026 was initiated by F.H. INVESTMENTS, Inc. (Dba Asteria Health) on Jan 26, 2026 and is designated Class II. Reason for recall: Presence of Foreign substance - potential presence of metal particulate matter The recall status is ongoing. Affected quantity: 1,464 pellets.

Recall details

Product Type
Drugs
Report Date
Feb 18, 2026
Initiation Date
Jan 26, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,464 pellets.

Product description

Testosterone 100mg Anastrozole 4mg , 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-4104-32

Reason for recall

Presence of Foreign substance - potential presence of metal particulate matter

Distribution pattern

Nationwide in the USA

Code information

Lot#: 254000105, Exp. 05/28/2026, 254000110, Exp. 08/07/2026; 254000112, 254000113, Exp. 09/26/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0331-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0331-2026. Report a data issue: hello@regdatalab.com.